Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment

American Academy of Dermatology Association Task Force on Drug Pricing and Transparency

Research output: Contribution to journalEditorial

Original languageEnglish (US)
Pages (from-to)577-578
Number of pages2
JournalJournal of the American Academy of Dermatology
Volume80
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

United States Food and Drug Administration

ASJC Scopus subject areas

  • Dermatology

Cite this

Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment. / American Academy of Dermatology Association Task Force on Drug Pricing and Transparency.

In: Journal of the American Academy of Dermatology, Vol. 80, No. 2, 01.02.2019, p. 577-578.

Research output: Contribution to journalEditorial

American Academy of Dermatology Association Task Force on Drug Pricing and Transparency 2019, 'Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment' Journal of the American Academy of Dermatology, vol. 80, no. 2, pp. 577-578. https://doi.org/10.1016/j.jaad.2018.09.016
American Academy of Dermatology Association Task Force on Drug Pricing and Transparency. / Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment. In: Journal of the American Academy of Dermatology. 2019 ; Vol. 80, No. 2. pp. 577-578.
@article{b0325756a81b425cae4955b9f0631eb8,
title = "Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment",
author = "{American Academy of Dermatology Association Task Force on Drug Pricing and Transparency} and Joerg Albrecht and Adewole Adamson and Barbieri, {John S.} and Bennett, {Daniel D.} and Kiracofe, {Elizabeth A.} and Kourosh, {A. Shadi} and Leslie, {Kieron S.} and Merola, {Joseph F.} and Josephine Nguyen and Elaine Siegfried and Nicole Strickland and Suzanne Olbricht and Asgari, {Maryam M.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1016/j.jaad.2018.09.016",
language = "English (US)",
volume = "80",
pages = "577--578",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment

AU - American Academy of Dermatology Association Task Force on Drug Pricing and Transparency

AU - Albrecht, Joerg

AU - Adamson, Adewole

AU - Barbieri, John S.

AU - Bennett, Daniel D.

AU - Kiracofe, Elizabeth A.

AU - Kourosh, A. Shadi

AU - Leslie, Kieron S.

AU - Merola, Joseph F.

AU - Nguyen, Josephine

AU - Siegfried, Elaine

AU - Strickland, Nicole

AU - Olbricht, Suzanne

AU - Asgari, Maryam M.

PY - 2019/2/1

Y1 - 2019/2/1

UR - http://www.scopus.com/inward/record.url?scp=85059752145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059752145&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2018.09.016

DO - 10.1016/j.jaad.2018.09.016

M3 - Editorial

VL - 80

SP - 577

EP - 578

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 2

ER -